Recon: AstraZeneca announces $15B China investment; UK says severe pancreatitis and death linked to GLP-1 drugs

• US vaccine changes lead some parents to question other newborn care (Reuters)
• Lilly, Repertoire enter up to $1.93 billion deal to develop autoimmune therapies (Reuters)
• How Opvee, Indivior’s powerful overdose antidote, went bust (STAT)
• Medicare proposes new transplant system rules that might spur use of less-than-perfect organs (STAT)
• Trump administration signals there’s widespread desire to curb Medicare Advantage (STAT)
• With new vaccine schedule secured, RFK Jr. allies head to statehouses (STAT)
• ARS Pharma TV ad for Neffy needled by FDA in untitled letter (Fierce Pharma)
• Sanofi vaccine sales face headwinds from US policy shifts (Reuters)
• US names HIV, arthritis drugs for next Medicare price talks (Reuters)
• Elon Musk's Neuralink says it has 21 participants enrolled in trials (Reuters)

• AstraZeneca sets out $15 billion China investment during Starmer visit (Reuters)
• Roche earnings edge up 5% as forex effects weigh on drug sales growth (Reuters)
• Pressure grows on ministers to end secrecy over UK medicines deal with Trump (The Guardian)
• Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff (Endpoints)
• Pakistan becomes latest Asian country to introduce checks for deadly Nipah virus (Reuters)
• UK Warns of Severe Pancreatitis, Deaths Tied to Wegovy, Mounjaro (Bloomberg)
• Covid Left Lasting Rise in Deaths in Rich Countries, Study Shows (Bloomberg)

• AI biotech founded by ex-Google CEO Eric Schmidt is raising $150 million (STAT)
• US FDA places clinical hold on Regenxbio's rare disease program (Reuters)
• ImmunityBio’s Soon-Shiong mischaracterized talks with FDA over cancer drug, sources say (STAT)
• Why I decided to share all my health information with ChatGPT Health (STAT)
• Agomab anticipates $182M IPO as it builds fibrosis pipeline (Endpoints)
• Summit says FDA will decide to approve its cancer drug by November (Endpoints)
• Sanofi vows to stay committed to vaccines as portfolio takes a hit (Endpoints)
• The disrupted fate of pharmacy startups (Endpoints)

• CDRH on track for review timelines despite staff cuts (MedTech Dive)
• Thermo Fisher forecasts 2026 profit below estimates on research funding cuts (Reuters)
• Cleveland Diagnostics names Michael Iskra CEO (MedTech Dive)
• Medtech M&A took off in the second half of 2025: report (MedTech Dive)
• Hey Doc, What’s That Sound? FDA Clearance Broadens Scope Of AI Heart Murmur Detection Platform (MedTech Insight)
• Illumina Pins 2026 Growth On Clinical Sequencing As Research Spending Stays Constrained (MedTech Insight)
• When Brain-Computer Interfaces Fail, Human Trial Participants Have Few Options (MedTech Insight)

• It’s Trendy to Mimic Breast Milk, But Formula Makers May Be Adding Risks (Bloomberg)
• Bain, Blackstone Among Suitors for UK Vitamin Maker Vitabiotics (Bloomberg)

• US life expectancy hit an all-time high in 2024, CDC says (STAT)
• HHS appoints 21 new members to federal autism advisory committee (STAT)
• Secretary Kennedy names new chair, 10 members to federal Alzheimer's advisory panel (Reuters)
• Kaiser Permanente, DOJ reach $556 million Medicare Advantage fraud settlement, the largest of its kind (STAT)
• Do pediatricians make large profits from vaccines? (STAT)